CSF levels of the somatodendritic protein MAP2 are increased in ALS and predict shorter survival
Our study shows that the somatodendritic protein MAP2 is a promising candidate CSF biomarker for ALS.
Authors
- Hayrettin Tumani (ORCID: https://orcid.org/0000-0002-1647-6201)
- Vincenzo Silani (ORCID: https://orcid.org/0000-0002-7698-3854)
- Nicola Ticozzi (ORCID: https://orcid.org/0000-0001-5963-7426)
- Patrick Oeckl (ORCID: https://orcid.org/0000-0002-7652-7023)
- Jan Vávra (ORCID: https://orcid.org/0000-0002-3171-6023)
- Maximilian Wiesenfarth (ORCID: https://orcid.org/0009-0004-0187-5973)
- Jochen Hans Weishaupt (ORCID: https://orcid.org/0000-0002-3399-9784)
- Zeynep Elmas
- Federico Verde (ORCID: https://orcid.org/0000-0002-3977-6995)
- Markus Otto (ORCID: https://orcid.org/0000-0003-4273-4267)
- Barbara Poletti (ORCID: https://orcid.org/0000-0003-4398-2051)
- Johannes Dorst (ORCID: https://orcid.org/0000-0001-6352-0909)
- Antonia Ratti
- Albert C. Ludolph
- Anna De Gobbi
Institutions
- University of Milan (IT)
- German Center for Neurodegenerative Diseases (DE)
- IRCCS Istituto Auxologico Italiano (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University Hospital Ulm (DE)
- Ferrari (Italy) (IT)
- Martin Luther University Halle-Wittenberg (DE)
Publication Details
- Journal
- Journal of Neurology Neurosurgery & Psychiatry
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1136/jnnp-2025-336208
- Citations
- 1
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Ministero della Salute